trial
as of 2026-07-01Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
NCTId NCT07101094
at a glance
Phase — · Recruiting
Enrollment 300 (estimated)
Sponsored by Bristol-Myers
Primary completion 2029-01-31
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Recruiting
Enrollment
300 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2025-09-22
Primary completion
2029-01-31
Eligibility
ALL · 18 Years
Interventions & indications
Indications
Sponsors
Bristol-MyersLead Sponsor
Sites
18 total
Orange, United StatesSan Jose, United StatesEvanston, United StatesBaltimore, United StatesBel Air, United StatesCatonsville, United StatesBelmont, United StatesBoston, United StatesSouth Dartmouth, United StatesOmaha, United StatesBelle Mead, United StatesNew York, United States
Facts & assertions
4 sourced
Enrollment
300
Phase
NA
Primary Completion Date
2029-01-31
Status
RECRUITING
relationships
The graph out of here
drug
lead_sponsor
company
indication
indication
indication